Concordantly, intestinal integrity and BT was ameliorated following the oral administration of BAs or FXR agonists in rodent models of cirrhosis, paralleled by an improvement of BT-associated inflammation and liver damage [4–6]. Here, NR1H4 is linked to Cirrhosis.